Purpose
PAMAM G5 dendrimer (P) was conjugated to Tat peptide (T), a cell penetrating peptide, in search of an efficient cellular delivery vehicle for antisense and siRNA oligonucleotides.
Methods
PAMAM G5 dendrimer was reacted with 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, sulfosuccinimidyl ester, sodium salt (BODIPY) for visualization to yield the conjugate BP. Bifunctional sulfosuccinimidyl 6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate (sulfo-LC-SMPT) was then used to conjugate primary amino groups of BP to cysteine derivatized Tat peptide to give the designed conjugate, BPT. This conjugate was complexed with antisense and siRNA oligonucleotides designed to inhibit MDR1 gene expression. NIH 3T3 MDR cells were used for the evaluation of biological activity of the conjugate.
Results
Both antisense and siRNA readily formed complexes with the synthesized BPT, introduced into NIH 3T3 MDR cells, and primarily accumulated in intracellular vesicles. MDR1 gene expression was partially inhibited by the antisense–BPT complex and weakly inhibited by the siRNA–BPT complex when both were tested at nontoxic levels of dendrimer. Conjugation with Tat peptide did not improve the delivery efficiency of the dendrimer.
Conclusions
Dendrimer–oligonucleotide complexes were moderately effective for delivery of antisense and only poorly effective for delivery of siRNA. Conjugation of the dendrimer with the Tat cell penetrating peptide failed to further enhance the effectiveness of the dendrimer.
Similar content being viewed by others
References
Y. Dorsett T. Tuschl (2004) Nat. Rev., Drug Discov. 3 318 Occurrence Handle10.1038/nrd1345 Occurrence Handle1:CAS:528:DC%2BD2cXis1Gkt74%3D
S. T. Crooke (2004) Annu. Rev. Med. 55 61 Occurrence Handle14746510 Occurrence Handle10.1146/annurev.med.55.091902.104408 Occurrence Handle1:CAS:528:DC%2BD2cXitVWrtb4%3D
R. L. Juliano H. Yoo (2000) Curr. Opin. Mol. Ther. 2 297 Occurrence Handle11249624 Occurrence Handle1:CAS:528:DC%2BD3cXksFWqu7s%3D
M. Manoharan (2002) Antisense Nucleic Acid Drug Dev. 12 103 Occurrence Handle12074364 Occurrence Handle10.1089/108729002760070849 Occurrence Handle1:CAS:528:DC%2BD38Xks12htbs%3D
E. L. Snyder S. F. Dowdy (2004) Pharm. Res. 21 389 Occurrence Handle15070086 Occurrence Handle10.1023/B:PHAM.0000019289.61978.f5 Occurrence Handle1:CAS:528:DC%2BD2cXhvF2lsbw%3D
S. Futaki (2005) Adv. Drug Deliv. Rev. 57 547 Occurrence Handle15722163 Occurrence Handle10.1016/j.addr.2004.10.009 Occurrence Handle1:CAS:528:DC%2BD2MXhslWgu7c%3D
A. Astriab-Fisher D. S. Sergueev M. Fisher B. R. Shaw R. L. Juliano (2000) Biochem. Pharmacol. 60 83 Occurrence Handle10807948 Occurrence Handle10.1016/S0006-2952(00)00310-5 Occurrence Handle1:CAS:528:DC%2BD3cXjtVCit78%3D
R. L. Juliano (2005) Curr. Opin. Mol. Ther. 7 132 Occurrence Handle15844620 Occurrence Handle1:CAS:528:DC%2BD2MXjvFSgtbY%3D
C. S. Braun J. A. Vetro D. A. Tomalia G. S. Koe J. G. Koe C. Russell Middaugh (2005) J. Pharm. Sci. 94 423 Occurrence Handle15614818 Occurrence Handle10.1002/jps.20251 Occurrence Handle1:CAS:528:DC%2BD2MXhtFOltb4%3D
R. Esfand D. A. Tomalia (2001) Drug Discov. Today 6 427 Occurrence Handle11301287 Occurrence Handle10.1016/S1359-6446(01)01757-3 Occurrence Handle1:CAS:528:DC%2BD3MXisF2nsbk%3D
H. Yoo P. Sazani R. L. Juliano (1999) Pharm. Res. 16 1799 Occurrence Handle10644065 Occurrence Handle1:CAS:528:DC%2BD3cXkt1egsw%3D%3D
M. Hussain M. Shchepinov M. Sohail I. F. Benter A. J. Hollins E. M. Southern S. Akhtar (2004) J. Control. Release 99 139 Occurrence Handle15342187 Occurrence Handle10.1016/j.jconrel.2004.06.009 Occurrence Handle1:CAS:528:DC%2BD2cXnt1Kjt7g%3D
R. Delong K. Stephenson T. Loftus M. Fisher S. Alahari A. Nolting R. L. Juliano (1997) J. Pharm. Sci. 86 762 Occurrence Handle9188063 Occurrence Handle10.1021/js960409f Occurrence Handle1:CAS:528:DyaK2sXjtV2rt7o%3D
H. Kobayashi M. W. Brechbiel (2004) Curr. Pharm. Biotechnol. 5 539 Occurrence Handle15579043 Occurrence Handle10.2174/1389201043376571 Occurrence Handle1:CAS:528:DC%2BD2cXhtVKmurnM
J. S. Zhang F. Liu L. Huang (2005) Adv. Drug Deliv. Rev. 57 689 Occurrence Handle15757755 Occurrence Handle10.1016/j.addr.2004.12.004 Occurrence Handle1:CAS:528:DC%2BD2MXitFertb0%3D
S. V. Ambudkar C. Kimchi-Sarfaty Z. E. Sauna M. M. Gottesman (2003) Oncogene 22 7468 Occurrence Handle14576852 Occurrence Handle10.1038/sj.onc.1206948 Occurrence Handle1:CAS:528:DC%2BD3sXotlaju70%3D
S. E. Kane D. H. Reinhard C. M. Fordis I. Pastan M. M. Gottesman (1989) Gene 84 439 Occurrence Handle2575560 Occurrence Handle10.1016/0378-1119(89)90518-0 Occurrence Handle1:CAS:528:DyaK3cXitlSrs7o%3D
B. H. Woo J. T. Lee M. O. Park K. R. Lee J. W. Han E. S. Park S. D. Yoo K. C. Lee (1999) Arch. Pharm. Res. 22 459 Occurrence Handle10549572 Occurrence Handle1:CAS:528:DyaK1MXnt1Gqtb8%3D
S. K. Alahari R. DeLong M. H. Fisher N. M. Dean P. Viliet R. L. Juliano (1998) J. Pharmacol. Exp. Ther. 286 419 Occurrence Handle9655887 Occurrence Handle1:CAS:528:DyaK1cXksFCgsL4%3D
D. Xu H. Kang M. Fisher R. L. Juliano (2004) Mol. Pharmacol. 66 268 Occurrence Handle15266017 Occurrence Handle10.1124/mol.66.2.268 Occurrence Handle1:CAS:528:DC%2BD2cXmtVylu7g%3D
H. Yoo R. L. Juliano (2000) Nucleic Acids Res. 28 4225 Occurrence Handle11058121 Occurrence Handle1:CAS:528:DC%2BD3cXovFKqurg%3D
H. M. Moulton M. H. Nelson S. A. Hatlevig M. T. Reddy P. L. Iversen (2004) Bioconjug. Chem. 15 290 Occurrence Handle15025524 Occurrence Handle10.1021/bc034221g Occurrence Handle1:CAS:528:DC%2BD2cXhs1Wmtrs%3D
M. Pooga U. Soomets M. Hallbrink A. Valkna K. Saar K. Rezaei U. Kahl J. X. Hao X. J. Xu Z. Wiesenfeld-Hallin T. Hokfelt T. Bartfai U. Langel (1998) Nat. Biotechnol. 16 857 Occurrence Handle9743120 Occurrence Handle10.1038/nbt0998-857 Occurrence Handle1:CAS:528:DyaK1cXlvFWktbw%3D
O. L. Padilla De Jesus H. R. Ihre L. Gagne J. M. Frechet F. C. Szoka SuffixJr (2002) Bioconjug. Chem. 13 453 Occurrence Handle12009933 Occurrence Handle1:CAS:528:DC%2BD38XjtVKhuro%3D
Acknowledgments
The authors would like to thank Professor Kang Choon Lee of Sungkyunkwan University of Korea for helpful discussion on the use of sulfo-LC-SMPT. This work was supported by NIH grant PO1 GM59299 to R.L.J.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, H., DeLong, R., Fisher, M.H. et al. Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides. Pharm Res 22, 2099–2106 (2005). https://doi.org/10.1007/s11095-005-8330-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-005-8330-5